Endocyte, Inc.

Purdue Research Foundation

Seattle Children's Hospital

Isis Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Mayo Foundation for Medical Education and Research

Christopher Paul Leamon

Iontcho Radoslavov Vlahov

Hari Krishna R Santhapuram

Philip Stewart Low

Paul Joseph Kleindl

Kevin Yu Wang

Joseph Anand Reddy

Yingjuan June Lu

Fei You

Matthew A Parker

Stephen J Howard

Apparao Satyam

Haiyan Chu

Leroy W Wheeler, Ii

Melissa Nelson

Marilynn Vetzel

Le-Cun Xu

Michael C Jensen

James Matthaei

Alicia Bloomfield

Ryan Dorton

Yu Wang

Michael Groaning

Katheryn Marie Stanford

Allen Ritter

Yong Gu Lee

Garth L Parham

Mark A Green

Chun-Yen Ke

Hari Krishna Santhapuram

Albert E Felten

Gregory D Vite

Francis Lee

Ning Zou

Lynn C Hartmann

Longwu Qi

Binh Nguyen

Chunhong Li

Yingcai Wang

Richard Messmann

Daniel S Reno

Katheryn M Stanford

Qingshou Chen

Navin Robert Charles Pinto

Julie Ruggieri Park

Christina M Dircksen

Nikki L Parker

Fei Yu

Jonathan M Shillingford

Leroy W Wheeler Ii

Kim Soong-Hoon

Phil Ronald Ellis

This disclosure relates to processes for preparing compounds that are useful in the treatment of disease, such as cancer, in mammals. In particular, the invention described herein pertains to processes for preparing compounds capable of targeting PSMA expressing cells and useful in the treatment of diseases caused by PSMA expressing cells, such as prostate cancer.

Methods for preparing PSMA conjugates

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Methods of use for CAR T cells

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Sequencing method for CAR T cell therapy

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

Compounds for positron emission tomography

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

Compositions and methods for CAR T cell therapy

Conjugates of antifolates, releasable linkers, and drugs, and pharmaceutical compositions containing them are described. The conjugates are useful for treating diseases arising from pathogenic cell populations. Methods for treating such diseases are also described.

Folate receptor binding conjugates of antifolates

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

Conjugates for treating diseases caused by PSMA expressing cells

The invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using radionuclide-based imaging. In particular, the invention described herein relates to conjugates and compositions for imaging, diagnosing, and/or monitoring diseases using positron emission tomography.

Conjugates for imaging

The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors as therapeutics and imaging agents. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in imaging methods and cancer therapy.

Carbonic anhydrase IX inhibitor conjugates and uses thereof

Described herein are compositions and methods for use in targeted drug delivery using cell-surface receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations.

Conjugates containing hydrophilic spacer linkers

This invention pertains to bivalent linkers, and the synthesis and use thereof. In particular, this invention pertains to the synthesis and use of bivalent linkers in preparing vitamin, drug, diagnostic agent, and/or imaging agent conjugates. The present invention includes divalent linkers, which are alternatively referred to as bivalent linkers, that may be used to couple, link, bond, attach, or otherwise associate two or more chemical entities. This coupling, linking, attachment, or association may be used in the formation of conjugates of such chemical entities. Those chemical entities include targeting ligands and receptor-binding ligands, such as vitamins. Those chemical entities also include drugs for treating various diseases or disease states, and imaging and diagnostic agents for diagnosing, detecting, or otherwise monitoring various diseases or disease states.

Bivalent linkers and conjugates thereof

The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

Conjugates for treating diseases

The disclosure provided herein pertains to CCK2R-drug conjugates. In particular, the disclosure pertains to CCK2R-drug conjugates that target the delivery of drugs to a mammalian recipient. Also described are methods of making and using CCK2R-drug conjugates.

CCK2R-drug conjugates

Growing community of inventors

West Lafayette, IN, United States of America

Christopher Paul Leamon